Biotech | November 13, 2021
Moderna presents data from Phase 1 study of mRNA Triplet programme
The interim data combines three mRNAs into one therapy injected directly into the tumour
The interim data combines three mRNAs into one therapy injected directly into the tumour
The trial met the primary endpoint of overall survival with a single priming dose of tremelimumab plus Imfinzi every four weeks vs. sorafenib
The CASPIAN Phase III trial in extensive-stage small-cell lung cancer is the longest survival follow-up ever reported for immunotherapy treatment in this setting
Subscribe To Our Newsletter & Stay Updated
